Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Aug;65(8):100588.
doi: 10.1016/j.jlr.2024.100588. Epub 2024 Jul 4.

Lipoprotein(a) and diet: consuming sugar-sweetened beverages lowers lipoprotein(a) levels in obese and overweight adults

Affiliations
Randomized Controlled Trial

Lipoprotein(a) and diet: consuming sugar-sweetened beverages lowers lipoprotein(a) levels in obese and overweight adults

Hayley G Law et al. J Lipid Res. 2024 Aug.

Abstract

Lipoprotein(a) [Lp(a)] contributes to cardiovascular disease risk. A genetically determined size polymorphism in apolipoprotein(a) [apo(a)], determined by the number of Kringle (K) repeats, inversely regulates Lp(a) levels. Nongenetic factors including dietary saturated fat influence Lp(a) levels. However, less is known about the effects of carbohydrates including dietary sugars. In this double-blind, parallel arm study among 32 overweight/obese adults, we investigated the effect of consuming glucose- or fructose-sweetened beverages providing 25% of energy requirements for 10 weeks on Lp(a) level and assessed the role of the apo(a) size polymorphism. The mean (±SD) age of participants was 54 ± 8 years, 50% were women, and 75% were of European descent. Following the 10-week intervention, Lp(a) level was reduced by an average (±SEM) of -13.2% ± 4.3% in all participants (P = 0.005); -15.3% ± 7.8% in the 15 participants who consumed glucose (P = 0.07); and -11.3% ± 4.5% in the 17 participants who consumed fructose (P = 0.02), without any significant difference in the effect between the two sugar groups. Relative changes in Lp(a) levels were similar across subgroups of lower versus higher baseline Lp(a) level or carrier versus noncarrier of an atherogenic small (≤22K) apo(a) size. In contrast, LDL-C increased. In conclusion, in older, overweight/obese adults, consuming sugar-sweetened beverages reduced Lp(a) levels by ∼13% independently of apo(a) size variability and the type of sugar consumed. The Lp(a) response was opposite to that of LDL-C and triglyceride concentrations. These findings suggest that metabolic pathways might impact Lp(a) levels.

Trial registration: ClinicalTrials.gov NCT01165853.

Keywords: Lp(a) metabolism; apolipoprotein; fructose; glucose; nutrition.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.

Figures

Fig. 1
Fig. 1
Opposite effects of consuming sugar-sweetened beverages on directly measured fasting LDL-C versus Lp(a) concentrations in all participants and by sugar types. Data are shown as mean (SEM) percent change in Lp(a) and directly measured LDL-C concentrations from baseline to week 10. Graphs are based on data from 32 participants for all, 15 participants for the glucose, and 17 participants for the fructose groups. a: P < 0.05; b: P < 0.01. Lp(a), lipoprotein(a).
Fig. 2
Fig. 2
Individual responses of Lp(a) and directly measured LDL-C concentrations to sugar-sweetened beverages consumption in all participants and by sugar types. Data are shown as percent change in Lp(a) and directly measured LDL-C concentrations from baseline to week 10. Graphs are based on data from 32 participants for all (top panel), 15 participants for the glucose (bottom left panel), and 17 participants for the fructose (bottom right panel) groups. Lp(a), lipoprotein(a).

Comment in

References

    1. Reyes-Soffer G., Ginsberg H.N., Berglund L., Duell P.B., Heffron S.P., Kamstrup P.R., et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association. Arterioscler. Thromb. Vasc. Biol. 2022;42:e48–e60. - PMC - PubMed
    1. Kronenberg F., Mora S., Stroes E.S.G., Ference B.A., Arsenault B.J., Berglund L., et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur. Heart J. 2022;43:3925–3946. - PMC - PubMed
    1. Sandholzer C., Hallman D.M., Saha N., Sigurdsson G., Lackner C., Csaszar A., et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum. Genet. 1991;86:607–614. - PubMed
    1. Enkhmaa B., Anuurad E., Berglund L. Lipoprotein(a): impact by ethnicity and environmental and medical conditions. J. Lipid Res. 2016;57:1111–1125. - PMC - PubMed
    1. Enkhmaa B., Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022;349:53–62. - PMC - PubMed

Publication types

Associated data